리포트 아카이브
전체 리서치
52페이지 중 45페이지 · 리포트 1238건
46/100
91Buffett
Paychex Investment Research Report
Paychex is the leading U.S. payroll and HR outsourcing provider for small and midsize businesses, with FY2025 revenue of $5.572 billion, net income of $1.657 billion, ROE of about 42%, and a dividend yield of about 5.1%. The Paycor acquisition has lifted net debt to roughly $5.0 billion, while the current price of $94.25 offers limited margin of safety and points to an ideal buy zone of $70 to $80. Research rating Watch: a high-quality cash-flow compounder worth monitoring, but not yet cheap enough for disciplined new capital.
40/100
66Buffett
In-Depth Value Investing Research on PACCAR Inc
PACCAR is a global premium heavy-duty truck platform (Kenworth, Peterbilt, DAF) combined with parts and financial services, with 2025 revenue of $28.4 billion and net income of $2.4 billion. The Parts segment's 24.3% margin anchors a durable moat while the Truck segment remains highly cyclical, and at the current price of $109.34 the stock is already near the optimistic valuation scenario. Rating: Watch.
43/100
84Buffett
PepsiCo: A Long-Term Owner's Perspective Investment Study
A global beverage-and-snack giant with a deep brand and distribution moat and steady free cash flow: 2025 revenue of $93.925 billion and FCF of $8.2 billion, with a TTM P/E of roughly 23x. But at the current $148.85 the stock already sits near the top of its reasonable intrinsic value range ($130-150), the margin of safety is not obvious, so the rating is Watch.
43/100
84Buffett
PayPal Holdings: A Deep-Dive Investment Study
A global digital payments platform: 439 million active accounts, $1.79 trillion in TPV, and buybacks that cut the share count 27.4% over three years. At the current $44.3 — about 8x P/E and 7x P/FCF — it sits well below a conservative intrinsic value of $52–60, with a moat that is narrowing rather than widening but odds that remain ample. Rating: Cautious Buy — a cheap, mid-quality platform worth buying carefully, not a no-track core holding.
48/100
83Buffett
Regeneron Pharmaceuticals Value Analysis from a Long-Term Business Owner's Perspective
Regeneron is an integrated innovative biologics leader anchored by Dupixent profit sharing and the handoff to EYLEA HD and Libtayo. The company generated $4.5 billion in 2025 net income and holds $15.8 billion in net cash, while the current price of $642.59 and 15.7x P/E sit in a holdable range with a thin margin of safety and an ideal buy zone of $450 to $550. Rating Watch: a high-quality compounder, but EYLEA erosion and pipeline uncertainty require patience on price.
44/100
57Buffett
Samsung Electronics: A Long-Term Owner's Perspective
A world-class collection of hard-tech assets with net cash of roughly KRW 119 trillion, but at the current price of KRW 299,500 it sits at the upper edge of the optimistic range with an insufficient margin of safety; fair intrinsic value is KRW 170,000–240,000, rating Watch.
44/100
34Buffett
UP Fintech Holding Limited Deep Value Analysis
UP Fintech, the parent of Tiger Brokers, is a cross-border online brokerage for Chinese-speaking investors, with 2025 revenue of $612 million, net profit of $171 million, and client assets of $60.8 billion. But its moat is shallow and its pricing power weak, and with China's cross-border regulatory enforcement escalating on 2026-05-22, the current $5.84 offers no margin of safety against conservative value. Rating: Watch.
56/100
82Buffett
TSMC: 가치투자 심층 연구
세계 최고의 첨단 로직 파운드리로, 순수 파운드리 시장의 약 70%를 점유하며 FY2025 매출 NT$3.81조와 59.9%의 매출총이익률을 기록했다. 현재 대만 상장 주가 NT$2235, TTM 주가수익비율(P/E) 약 29.5x 수준에서 주가는 이미 적정가치를 웃돌며 안전마진이 얇다. 등급 관찰: 세계 최고 수준의 사업이지만, 주가는 더 이상 완충 여지를 남기지 않는다.
U.S. Market Close Daily | 2026-05-22
The Dow set a record high and the S&P 500 logged its eighth straight weekly gain, with AI infrastructure plus a small-cap and equal-weight broadening keeping risk appetite alive, yet rising oil prices, long-end yields, and inflation expectations make chasing strength less attractive. Rating Watch: indexes are strong and breadth is improving, but upside increasingly hinges on earnings delivery rather than valuation expansion.
50/100
89Buffett
Monolithic Power Systems Deep Value Investment Analysis
Monolithic Power Systems is a high-quality analog and power-management semiconductor company with net cash, strong cash flow, and moat characteristics rooted in system-level power design and design-in stickiness. The core issue is price: at $744.90, the stock already reflects stretched AI growth expectations, while fair intrinsic value is closer to $380 to $460 and the margin of safety is insufficient, especially given the 2024 financial restatement and unresolved material weakness in internal control. Report rating Watch: a durable compounder worth tracking closely, but not a conservative buy at the current price.
49/100
96Buffett
Deep Value Investment Analysis of Monster Beverage Corporation
A great business at a poor price. Monster is focused on energy drinks, with a strong brand and Coca-Cola distribution moat, high FCF conversion, and a net-cash balance sheet; but the current $86.35 price implies 44x PE and roughly 43x P/FCF, with an FCF yield of only about 2.3%, below the 10-year U.S. Treasury yield and leaving almost no margin of safety. Rating Watch: the business deserves long-term tracking, but the current valuation does not offer a conservative entry point.
56/100
47Buffett
MercadoLibre: 장기 사업주의 관점에서 본 투자 분석
라틴아메리카의 커머스-결제-물류-광고-신용 플라이휠 위에 구축된 고품질 복리 성장 플랫폼이지만, 약 $1,677의 주가는 이미 낙관적 시나리오를 반영해 주주 이익의 58배가 넘는 수준이며 안전마진이 충분하지 않다. 공정가치는 $750–1,000이며, 더 매력적인 매수 구간은 $600–800이다. 등급 관찰: 훌륭한 기업이지만 훌륭한 진입 시점은 아니다.
42/100
63Buffett
MDLZ: Investment Research Through a Long-Term Business Owner's Lens
A good business, good brands, and good cash flow, but at roughly $61.50 today the price leaves an insufficient margin of safety for conservative long-term investors; fair intrinsic value $48–60, ideal buy range $42–50.
43/100
Microchip Technology: A Deep Dive from a Long-Term Business Owner's Perspective
A good company, but one now trading beyond a good price. Analog/MCU/embedded semiconductors sit in the early innings of recovery, and near $91 the stock looks more like paying up for that recovery than acquiring a business at a discount; fair intrinsic value is $50–65 and the ideal buy range is $45–55. Rating: Watch.
48/100
45Buffett
Marriott International Deep Value Analysis
Marriott is one of the highest-quality global asset-light hotel platforms. At about $370.56, the stock already prices in high-quality growth, with a fair intrinsic value range of $220 to $260 and an ideal buy range of $170 to $210. Rating Watch: a durable compounder, but the current price leaves too little margin of safety.
49/100
90Buffett
Lam Research from a Long-Term Business Owner's Perspective
Lam Research is a high-barrier, deeply cyclical leader in front-end wafer fabrication equipment, with process stickiness and a growing service mix that strengthen cash-flow resilience. At about USD 302 as of 2026-05-22, however, a 56x PE and only a 1.5%–1.8% earnings yield already discount years of strong growth, leaving little margin of safety. Rating Watch: a high-quality business that belongs on the long-term watchlist, but fair intrinsic value is closer to USD 100–140 than today's price.
47/100
48Buffett
In-Depth Value Investment Analysis of Linde plc
Linde plc is a world-class leader in industrial gases and a classic high-quality compounder. Yet at roughly $514 per share, the stock trades near 34 times PE, close to the upper end of an optimistic case, with fair intrinsic value around $340-450 and an ideal buy range of $330-400. Report rating Watch: an excellent business, but the current price leaves too little margin of safety.
52/100
93Buffett
KLA Corporation: A Deep Value Investment Analysis
Great company, bad price. KLA is an exceptionally high-quality, long-term compounding business in semiconductor process control, but at roughly 52x PE and roughly 60x FCF today, the price has already pulled forward too much future return and offers no margin of safety. Reasonable intrinsic value range: $850-$1,100 per share. Rating Watch: a world-class franchise that is simply too expensive to commit fresh capital at current levels.
35/100
Kraft Heinz: A Value Investing Deep Dive
A cheap-but-not-exceptional defensive value stock. At the current $23.54, KHC trades at roughly 8–9x conservative owner earnings with a 6.8% dividend yield; a margin of safety exists but it is thin. The biggest swing factor is whether the added spending in 2026–2027 can stabilize volume and share. Rating Cautious Buy: a high-cash-flow, low-growth, undervalued consumer name worth a small-to-moderate position, not a top-tier compounder.
45/100
Keurig Dr Pepper: A Long-Term Business Owner's Perspective
Good assets, complex structure. KDP's North American beverage business and K-Cup coffee assets are solid, but the JDE Peet's acquisition and the planned subsequent split turn it into a capital-allocation trade that still has to be proven; conservative/fair/optimistic intrinsic value of $13–16 / $21–29 / $31–37, ideal buy below $20–22.
52/100
83Buffett
Intuitive Surgical: A Long-Term Business Owner's Research Report
The leader in robot-assisted surgery, with recurring revenue at 84% of the total and a moat built on its ecosystem rather than any single product. But as of 2026-05-22 the stock trades around $439.80 at a trailing P/E of roughly 53.4x, a clear premium to a reasonable intrinsic value of $250-340 with no margin of safety. Rating Watch: a superb business priced for a near-flawless decade.
50/100
94Buffett
Intuit Inc. Deep Value Analysis
A high-quality, capital-light, cash-generative tax and finance software platform with FY2025 revenue of $18.831 billion. The core thesis is that Intuit remains a durable platform, but TurboTax's moat is being retested by AI and policy change, making roughly $307 look closer to fair value than a clear bargain. Rating Watch: a strong business with insufficient margin of safety at the current price.
45/100
Insmed: A Deep-Dive Value Investing Research Report
A high-quality but high-expectation respiratory-specialty biotech. ARIKAYCE and BRINSUPRI are scarce respiratory assets, but at roughly $109.5 the stock already prices in multiple successes, owner earnings remain negative, and the margin of safety is thin. Rating Watch: a good company at an ungenerous price, with a fair buy range of $55–70.
47/100
92Buffett
In-Depth Value Research on IDEXX Laboratories
IDEXX Laboratories is a rare high-quality compounder in companion-animal diagnostics. Its 2025 free cash flow of about $1.057 billion and durable moat are impressive, but the price anchor of roughly $563 per share already discounts much of that excellence and leaves little margin of safety. Report rating Watch: keep it high on the watchlist and wait for better odds.